Results 41 to 50 of about 2,000 (177)

Machine Learning‐Enhanced Random Matrix Theory Design for Human Immunodeficiency Virus Vaccine Development

Advanced Intelligent Discovery, EarlyView.
This study integrates random matrix theory (RMT) and principal component analysis (PCA) to improve the identification of correlated regions in HIV protein sequences for vaccine design. PCA validation enhances the reliability of RMT‐derived correlations, particularly in small‐sample, high‐dimensional datasets, enabling more accurate detection of ...
Mariyam Siddiqah, Muhammad Zulqarnain Zeb, Muhammad Husnain Zeb, Babar Shabbir   +3 more
wiley   +1 more source

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals

, 2022
Objectives We evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades.
Bouba, Yagai, Ceccherini-Silberstein, Francesca, Sosso, Samuel Martin, Santoro, Maria, Takou, Désiré Komego, Ngueko, Aurelie Minelle Kengni, Fokam, Joseph, Teto, Georges, Fabeni, Lavinia, Dambaya, Béatrice, Ndjolo, Alexis, Carioti, Luca, Nka, Alex Durand, Pabo, Willy, Semengue, Ezéchiel Ngoufack Jagni, Colizzi, Vittorio, Armenia, Daniele, Perno, Carlo-Federico   +17 more
core   +1 more source

ID060 Oportunidades no manejo de indivíduos com vírus da imunodeficiência humana altamente experientes no tratamento

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução A supressão virológica figura como um dos principais objetivos do tratamento da síndrome da imunodeficiência humana. Entretanto, pessoas altamente experientes em tratamento com vírus da imunodeficiência humana podem não alcançar a ...
Kelli Carneiro de Freitas Nakata, Helder Cássio de Oliveira   +1 more
doaj   +1 more source

Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV‑1 Treatment and Pre-exposure Prophylaxis

Journal of Medicinal Chemistry
The HIV capsid is essential to the virus lifecycle, making it a promising target for therapeutic intervention. In 2006, a screening campaign was initiated to identify small molecules capable of disrupting the protein–protein interactions required for ...
E. Canales, Winston C. Tse, S. Schroeder, Chienhung Chou, Qi Liu, Jennifer R. Zhang, S. Lazerwith, P. Morganelli, R. Saito, Gediminas J. Brizgys, Jiayao Li, Qiaoyin Wu, Michael Graupe, R. Halcomb, Manoj Desai, Carina E. Cannizzaro, E. Hu, Jason K. Perry, A. Villaseñor, J. Somoza, Ryan D Ferrao, S. Swaminathan, Jim Zheng, Bing Lu, J. Mwangi, K. Wang, Raju Subramanian, Bill J Smith, G. Rhodes, W. Rowe, D. Sauer, L. Lad, Giuseppe A. Papalia, Sheila Clancy, G. Stepan, Helen Yu, R. Sakowicz, Bing Shi, Gavin Carr, Rujuta A. Bam, Luong K. Tsai, Eric Singer, Derek Hansen, Andrew Mulato, S. Yant, T. Cihlář, John O. Link   +46 more
semanticscholar   +1 more source

Operationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Regulatory inconsistency across Africa causes duplicative assessments, prolonged approvals, and delayed medical access. To inform the African Medicines Agency (AMA), the African Medicines Regulatory Harmonisation (AMRH) piloted Africa's first continental scientific evaluation of human medicinal products.
Alex Juma Ismail, Lerato Moeti, Delese Mimi Darko, Stuart Walker, Sam Salek   +4 more
wiley   +1 more source

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir

mBio
Lenacapavir (LEN) is the first-in-class viral capsid protein (CA) targeting antiretroviral for treating multi-drug-resistant HIV-1 infection. Clinical trials and cell culture experiments have identified resistance-associated mutations (RAMs) in the ...
Lorenzo Briganti, Arun S. Annamalai, Stephanie M. Bester, Guochao Wei, Jonathan R. Andino-Moncada, S. P. Singh, A. Kleinpeter, Meghna Tripathi, Binh Nguyen, Rajalingam Radhakrishnan, P. Singh, Juliet Greenwood, Lauren I. Schope, Reed Haney, Szu-Wei Huang, Eric O. Freed, Alan N. Engelman, A. Francis, M. Kvaratskhelia   +18 more
semanticscholar   +1 more source

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVResearch in context

EBioMedicine, 2023
Summary: Background: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1 pre-exposure ...
Adrienne E. Swanstrom, Robert J. Gorelick, Jorden L. Welker, Fabian Schmidt, Bing Lu, Kelly Wang, William Rowe, Matthew W. Breed, Kristin E. Killoran, Joshua A. Kramer, Duncan Donohue, James D. Roser, Paul D. Bieniasz, Theodora Hatziioannou, Cathi Pyle, James A. Thomas, Charles M. Trubey, Jim Zheng, Wade Blair, Stephen R. Yant, Jeffrey D. Lifson, Gregory Q. Del Prete   +21 more
doaj   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

, 2023
Background: Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults ...
David A. Wheeler, Wang H., Joseph P. McGowan, Peter J. Ruane, Segal-Maurer S., Winai Ratanasuwan, William Sanchez, Theo Hodge, Krittaecho Siripassorn, Moti N. Ramgopal, Catherine M. Creticos, Daniel S. Berger, Avihingsanon A., Workowski K., James Sims, Sorana Segal-Maurer, Benoit Trottier, Takuma Shirasaka, Kimberly Workowski, Chien-Ching Hung, Gary Ian Sinclair, Andrea Antinori, Gary J. Richmond, Martin S Rhee, Andrew Wiznia, Gordon E. Crofoot, Hadas Dvory-Sobol, Hui Wang, Dvory-Sobol H., Jean-Michel Molina, Edwin DeJesus, Jason Brunetta, Ratanasuwan W., Molina J. -M., Yazdan Yazdanpanah, Jared M Baeten, Onyema Ogbuagu, Mezgebe Berhe, Brinson C., Ellen Koenig, Hans-Jurgen Stellbrink, Antonella Castagna, Nicolas Margot, Josep Mallolas, Debbie Hagins, Baeten J. M., Yoshiyuki Yokomaku, Cynthia Brinson, Christine Zurawski, Yazdanpanah Y., Ploenchan Chetchotisakd, castelli f., Margot N., Kenneth Lichtenstein, Sylvie Ronot-Bregigeon, Trottier B., Anchalee Avihingsanon, Francesco Castelli, Mohammed Rassool, Antinori A., Rhee M. S., Olayemi Osiyemi, Ogbuagu O.   +62 more
core   +1 more source

HIV-1 capsid stability enables inositol phosphate-independent infection of target cells and promotes integration into genes.

PLoS Pathogens, 2023
The mature HIV-1 capsid is stabilized by host and viral determinants. The capsid protein CA binds to the cellular metabolites inositol hexakisphosphate (IP6) and its precursor inositol (1, 3, 4, 5, 6) pentakisphosphate (IP5) to stabilize the mature ...
Gregory A Sowd, Jiong Shi, Ashley Fulmer, Christopher Aiken   +3 more
doaj   +1 more source